Form 4: Enanta Pharmaceuticals Director Lesley Russell Acquires Stock Options

Director Lesley Russell acquired stock options in Enanta Pharmaceuticals, exercisable over the next year.

Summary

• Lesley Russell, a director of Enanta Pharmaceuticals, acquired 15,700 stock options on March 13, 2025, at an exercise price of $6.83.
• The options vest monthly over one year, starting from the grant date, with the final installment vesting before the 2026 annual meeting of stockholders.
• Russell also granted a power of attorney to several individuals to handle SEC filings related to Enanta Pharmaceuticals securities.
• The power of attorney is effective until Russell is no longer required to file Forms 3, 4, and 5, or until revoked.

Sentiment

Score: 6

Explanation: Neutral sentiment as it's a routine disclosure of stock option grants to a director. It doesn't inherently indicate positive or negative performance.

Positives

• The acquisition of stock options by a director could be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

This is a standard SEC filing related to insider transactions. It is common for directors and officers of publicly traded companies to receive stock options as part of their compensation.

Comparison to Industry Standards

• Stock option grants are a typical component of executive compensation packages in the pharmaceutical industry.
• The vesting schedule of monthly installments over one year is a fairly standard practice.
• Comparing the size of the grant to those of directors at comparable pharmaceutical companies would provide further context.

Stakeholder Impact

• The stock option grant could potentially incentivize the director to work towards increasing shareholder value.

Key Dates